Patrick (Paddy) Mallon
机构: Centre for Experimental Pathogen Host Research, University College Dublin
每年引用次数
引用次数
引用: 7,833
H-指数: 49
I10-指数 : 139
出版物: 399
Molecular identification of Acinetobacter sp. in a patient with culture-negative endocarditis
P.W.G. Mallon , B.C. Millar , J.E. Moore , P.G. Murphy
Clinical Microbiology and Infection 6 ( 5) 277 -278
11
2000
Quality of life assessment in people living with and without HIV: UPBEAT study
E. Alvarez , A.M. Barry , A.G. Cotter , C. Sabin
Journal of virus eradication 2 25
2016
The HIV Care Cascade and sub-analysis of those linked to but not retained in care: the experience from a tertiary HIV referral service in Dublin Ireland.
P. McGettrick , B. Ghavami-Kia , W. Tinago , A. Macken
Hiv Clinical Trials 18 ( 3) 93 -99
11
2017
Insulin resistance in treated HIV infection.
E.R. Feeney , P.W.G. Mallon
Best Practice & Research Clinical Endocrinology & Metabolism 25 ( 3) 443 -458
28
2011
Fractures and the gut microbiome.
Tara McGinty , Paddy W.G. Mallon
Current Opinion in Hiv and Aids 13 ( 1) 28 -37
16
2018
Community-acquired Klebsiella pneumoniae liver abscess: an emerging infection in Ireland and Europe.
R. Moore , D. O’Shea , T. Geoghegan , P. W. G. Mallon
Infection 41 ( 3) 681 -686
58
2013
The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
A. Winston , P. W. G. Mallon , C. Satchell , K. MacRae
Clinical Infectious Diseases 44 ( 11) 1475 -1483
15
2007
Changes in bone biomarkers in antiretroviral naïve HIV-infected men randomised to nevirapine/lopinavir/ritonavir (NVP/LPV/R) or zidovudine/lamivudine/lopinavir/ritonavir (AZT/3TC/LPV/R) help explain limited loss of bone mineral density over first 12 months
B.F. Murray⁎ , M.G. van Vonderen , P.W. Mallon , P. Doran
Bone 50
8
2012
Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial
Arribas JR Bernardino JI , Mocroft A , Mallon PW , Wallet C
The Lancet HIV 2 ( 11) e464 -e473
52
2015
The renal-bone axis in older people living with HIV on stable antiretroviral therapy: A sub-analysis of the GS-US-104-0423 study
Elena Alvarez , Lucy Campbell , Willard Tinago , Alejandro Garcia-Leon
Antiviral Therapy 27 ( 4) 13596535221094898 -13596535221094898
2
2022
Cognitive function and depression in HIV-positive individuals and matched controls
F Post , J Anderson , M Johnson , P Mallon
2016
Investigating the intersection of substance use and high-risk sexual behaviours, and their associations with mental health, in people living with HIV
A Pozniak , F Post , P Mallon , A Winston
2017
Real-world comparative outcomes of integrase inhibitor-based first-line ART
S Taylor , C Smith , N Marshall , I Reeves
2017
Oxidative stress during acute respiratory exacerbations in cystic fibrosis
L T McGrath , P Mallon , L Dowey , B Silke
Thorax 54 ( 6) 518 -523
71
1999
O322 Bone disease and HIV – together for the long term
P Mallon
Journal of the International AIDS Society 11 ( 1) 1 -1
2008
Antiretroviral regimen complexity as a predictor of adherence
C Boyle , A Wilson , G Treacy , G Sheehan
Journal of the International AIDS Society 13 ( 4) 121
2010
Development of a single-tube, low-cost, analytical process to extract, separate and determine efavirenz and rifampicin plasma concentrations in HIV/TB co-infected patients.
D Fox , R O’Connor , P Mallon , G McMahon
Journal of the International AIDS Society 13 ( 4) 149
1
2010
The role of tenofovir alafenamide in future HIV management.
A Antela , C Aguiar , J Compston , BM Hendry
Hiv Medicine 17 4 -16
30
2016
Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study
SL Pett , J Amin , A Horban , J Andrade‐Villanueva
Hiv Medicine 19 ( 1) 65 -71
3
2018
Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial.
P Olal , G Pimundu , P Segonga , F Ssali
Clinical Infectious Diseases 68 ( 7) 1184 -1192
7
2019